Moloney murine leukemia virus induces myeloid leukemia when inoculated intravenously into pristaneprimed adult BALB/c mice. One hundred percent of these tumors show insertional activation of the c-myb proto-oncogene, and reverse transcriptase PCR assays have shown that the c-myb activation could be detected soon after infection. We tested BALB/c and NIH Swiss mice that had been inoculated as newborns with Moloney murine leukemia virus, under which conditions they develop T lymphomas exclusively. Reverse transcriptase-PCR assays indicated that c-myb activations were detectable soon after neonatal infection. However, none of the resulting T lymphomas contained c-myb activations. The implications of these results to the timing of proto-oncogene activations in leukemogenesis and the specificity of proto-oncogene activations for different diseases are discussed.
Moloney murine leukemia virus (M-MuLV) has been extensively studied as a leukemogenic agent. When inoculated into neonatal NIH Swiss or BALB/c mice, it induces T lymphomas with 100% incidence and with a mean latency of 16 to 17 weeks (5) . More recently, it has been shown that intravenous inoculation of M-MuLV into adult pristane-treated BALB/c mice leads to development of the myeloid leukemia called M-MuLV-induced myeloid leukemia (MML). This leukemia has a promonocytic phenotype and occurs with a 50% incidence and mean latency of 14 to 15 weeks (13, 14) . Thus, depending on the method of infection, the pathogenic outcomes are different.
Leukemogenesis by M-MuLV and other nonacute retroviruses is a multistep process. One step involves insertional activation of cellular proto-oncogenes by enhancers or promoters carried by the retroviral long terminal repeat (3, 5, 7) . In mice, T lymphomas induced by M-MuLV predominantly show long terminal repeat activations of the proto-oncogenes c-myc, pim-1, and pvt-1. On the other hand, MMLs induced by the same virus in pristane-primed BALB/c mice uniformly show activation of c-myb, and the proto-oncogenes associated with T lymphomas are not involved (13) .
In addition to proto-oncogene activation, M-MuLV requires other steps for leukemogenesis. For T lymphomagenesis, the other events include (i) generation of envelope gene (mink cell focus-forming [MCF]) recombinants (2) and (ii) preleukemic hematopoietic changes characterized by generalized splenic hyperplasia and defects in bone marrow hematopoiesis (4, 9) . For MML induction, pristane priming is essential for leukemia induction but not for insertional mutagenesis of c-myb (10, 14) . Therefore, the inflammatory granuloma induced by pristane probably collaborates in neoplastic development by stimulating myelopoiesis and providing an immunosuppressive environment (14) .
Traditionally, proto-oncogene activation has been viewed as a late event in leukemogenesis by murine leukemia viruses. For instance, studies of preleukemic mice indicated that the bulk of c-myc or pim-1 activations occurred at relatively late times in AKR mice infected with a pathogenic MCF recombinant (12) . However, our studies of adult pristane-primed BALB/c mice infected with M-MuLV have led to a different conclusion (10) . These experiments were greatly facilitated by the fact that the c-myb activation in MML results from proviral insertion into one of three c-myb introns and ''promoter insertion'' fusion transcripts containing M-MuLV long terminal repeat (R and U5) and gag sequences fused to downstream c-myb exons. A cryptic splice site in M-MuLV gag is joined to myb to create novel gag-myb fusion RNAs (10) . This fusion allowed development of an extremely sensitive reverse transcriptase (RT)-PCR assay for cells containing the c-myb activation. This assay indicated that c-myb-activated cells could be detected within 2 weeks of infection in the bone marrow of inoculated adult mice (10) . Thus, proto-oncogene activation was an early event in this system. The results also indicated that other steps besides c-myb activation were required for the development of the myeloid tumors, since the activations occurred well before emergence of the tumors.
In light of the finding that c-myb activation was an early event in MML development in BALB/c mice infected as adults, we wondered if c-myb activation might also be detectable at preleukemic times in mice infected neonatally by M-MuLV. As indicated above, such mice develop T lymphomas exclusively. Both infected BALB/c and NIH Swiss mice were tested to determine if any c-myb activation was strain specific. NIH Swiss and BALB/c mice were inoculated intraperitoneally with 2 ϫ 10 5 XC cell PFU (13) of M-MuLV as neonates. At 4 weeks postinfection, RNA was extracted from the bone marrow and spleens. Five micrograms of each RNA sample was subjected to reverse transcription and two cycles of nested PCR amplification with forward primers specific for the gag region of M-MuLV and reverse primers for exon 4 of c-myb as described previously (10, 11) . The resulting RT-PCR products were then analyzed by gel electrophoresis and Southern blot hybridization with labeled gag-myb junction probes specific for exons 4, 3, and 2 (10, 11) . The results are shown in Fig. 1 and summarized in Table 1 . All six infected BALB/c mice contained detectable c-myb rearrangements in their bone marrow and/or spleen. This event was multiclonal, since all animals showed integrations adjacent to more than one exon. Moreover, bone marrow and spleen from the same animals frequently showed different spectra of rearrangements. Five of six infected NIH Swiss mice also showed rearrangements at c-myb. These results indicated that c-myb rearrangements similar to those seen for adult BALB/c mice infected intravenously with M-MuLV could easily be detected in hematopoietic cells of neonatally inoculated NIH Swiss or BALB/c mice at early preleukemic times.
Since the experiment whose results are shown in Table 1 indicated that proviral c-myb activations were readily detectable in most mice inoculated neonatally with M-MuLV, we reexamined the end stage T lymphomas induced by this virus for c-myb activations, as well as for insertions near c-myc and pim-1. DNA from thymic tumors resulting from neonatal inoculation of six NIH Swiss and six BALB/c mice was extracted and analyzed by Southern blot hybridization for gene rearrangements in the three proto-oncogenes and also the T-cell receptor beta (TCR␤) locus. As shown in Table 2 , all of the tumors were T lymphoid as defined by rearrangement of the TCR␤ locus (1). Four of six NIH Swiss mice showed insertions at c-myc or pim-1, consistent with the frequency observed in previous studies (6) , while two of six BALB/c mice showed insertions at these loci. In contrast, none of the 12 end stage tumors contained proviral integrations at c-myb, consistent with previous studies. Thus, despite the fact that c-myb activations were readily detected in hematopoietic tissues of neonatally inoculated mice at preleukemic times, c-myb activation did not occur in the cells that ultimately developed into the T lymphomas.
In light of the fact that the resulting T lymphomas lacked c-myb activations while the preleukemic mice showed these activations, we expanded the studies to include the thymus (Fig. 2) . This tissue was of interest for two reasons: (i) an M-MuLV-induced T lymphoma is largely a neoplasm of thymocytes, and (ii) hematopoietic cells of the thymus are largely committed to the T-lymphoid lineage while bone marrow and spleen contain hematopoietic progenitors for most lineages. Table 3 summarizes data from a time course experiment that analyzed c-myb rearrangements in neonatally inoculated mice at different ages. Several points emerged. First, c-myb rearrangements could be detected in preleukemic thymus tissue, particularly at early times. Second, as discussed for Table 1 , different organs within the same animal showed different patterns of c-myb rearrangements. This finding also argued against the presence of a potential artifact that the positive signal for c-myb rearrangements in the thymus resulted from circulating blood cells; if this were the case, then all organs would be expected to show the same pattern. Indeed, for animal 5, the only tissue showing a c-myb rearrangement was the thymus. Animal 12 was also interesting. This was a leukemic 12-week-old NIH Swiss mouse that showed c-myb rearrangements in the bone marrow and spleen (likely to be mixtures of tumor cells and normal cells) and no rearrangements in the thymus. At 12 weeks postinfection, the thymus was virtually exclusively tumor tissue.
These results lead to several conclusions about the role of proto-oncogene activation in leukemogenesis. First, early proviral activation of c-myb can be readily documented in mice neonatally infected with M-MuLV. The frequency of this pro-
FIG. 1. (A) gag-myb RNA in tissues of six neonatally infected BALB/c (A)
and six NIH Swiss mice (B) at 4 weeks postinfection. RNA extracted from tissues of mice was reverse transcribed and subjected to two rounds of amplification as previously described (10, 11) . Blots were hybridized to junction probes JEX-4, -3, and -2. The lanes are numbered by animal numbers. bm, bone marrow; s, spleen. cess is evident from the multiple rearrangements detectable in a single animal. This appears to be a general phenomenon, and it extends our previous observations of BALB/c mice infected as adults. It is therefore difficult to attribute the latency of M-MuLV-induced leukemia exclusively to the time required for an insertion next to the appropriate proto-oncogene to occur. Another point is that while c-myb activation in neonatally infected mice presumably leads to limited expansion of those cells (to the point where they can be detected by RT-PCR), they apparently do not have the potential to develop into T lymphomas, since all the tumors lacked c-myb activations (either by Southern blot hybridization or RT-PCR). One possibility is that the c-myb activations occurred in hematopoietic cells committed to nonlymphoid (e.g., myelomonocytic) lineages, although the ready detection of c-myb rearrangements in the thymus must then be explained. Alternatively, the c-myb activations could provide a tumorigenic signal to myelomonocytic but not T-lymphoid cells.
While the results shown in Table 3 indicated that the thymuses of preleukemic mice frequently contain c-myb rearrangements, we have not investigated whether the signals represent hematopoietic cells (thymocytes) or stromal elements. Stromal cells include epithelial cells, adipocytes, and macrophages; it is noteworthy that thymic macrophages are early sites of replication for MCF recombinant viruses after murine leukemia virus infection (8) .
Finally, these experiments suggest that since there are sufficient rounds of viral infection at early times for frequent c-myb activations, early insertional activation of other protooncogenes (including those such as c-myc, pim-1, and pvt-1 that contribute to T lymphomagenesis) may also occur. Thus, the tempo of M-MuLV-induced T lymphomas may not be governed by the rate at which proviral insertions near protooncogenes takes place. Secondary virus-induced or spontaneous events are likely required for full leukemic transformation of a cell containing a proto-oncogene activation. Moreover, early or preleukemic events may actually temporally follow proto-oncogene activations in some developing leukemic cells. In any event, these results reinforce the notion of the multistep nature of leukemogenesis and the requirement of specific molecular changes for development of tumors of a particular lineage. FIG. 2 . gag-myb RNA in tissues of neonatally infected BALB/c and NIH Swiss mice at various times postinfection. The animal numbers above the panels correspond to those in Table 3 , which shows the conditions of infection. Each RT-PCR was analyzed as described in the legend to Fig. 1. (A) JEX-4 probe; (B) JEX-3 probe; (C) JEX-2 probe. bm, bone marrow; s, spleen; t, thymus. ϩ, RT-PCR on the MML tumor cell line used for the assay represented in Fig. 1A and B. Ϫ, control. a Summary of proviral insertions in the c-myb locus detected by RT-PCR in 4-week-old mice.
b Number of animals positive for gag-myb RNA in one or more tissues with either the JEX-4, -3, or -2 probe and total number of animals in the group.
c Number of mice positive for each specific gag-myb fusion. a NIH Swiss and BALB/c mice neonatally inoculated with 5 ϫ 10 5 XC cell PFU of M-MuLV were sacrificed when moribund. High-molecular-weight DNA was extracted from end stage tumors and subjected to Southern blot analysis as previously described (6) .
b Rearrangement of the TCR␤ locus is diagnostic of T-cell-derived lymphoblastic lymphoma. Proviral insertions adjacent to the proto-oncogenes c-myc, pim-1, and c-myb were detected as previously described (6, 10) . Values represent the number of mice affected as a fraction of the total of the group. 
